4-乙酰氨基-N-(2'-氨基苯基)-苯甲酰胺

¥1411.20
LClabs
美国
2022-08-24 09:05

上海经科化学科技有限公司

我要认领
上海经科化学科技有限公司
李经理
13524423207 021-54997581
jingkehuaxue@163.com
472482400
产品属性
产品说明


供应商:上海经科化学科技有限公司 


服务热线:400-0199-638 


QQ:472482400(上海经科)


微信号:shjkchem 


活动:消费积分可换充值卡!


本试剂(4-乙酰氨基-N-(2'-氨基苯基)-苯甲酰胺)
仅供科研实验使用,不得用于其他用途!

简介:
货 号:LC1-C-2606
名 称:4-乙酰氨基-N-(2'-氨基苯基)-苯甲酰胺
别 名:CI-994 Free Base
C A S :112522-64-2
分子量
:269.3
分子式:C15H15N3O2
纯 度:HPLC/TLC:>99%
说 明:Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 66 mg/mL; very poorly soluble in ethanol; very poorly soluble in water; maximum solubility in plain water is estimated to be about 25-100 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A.
文 献
:CI-994 is a histone deacetylase (HDAC) inhibitor and induces histone hyperacetylation in living cells. CI-994 inhibited HDAC-1 and HDAC-2 but not the prototypical histone acetyltransferase GCN5. Kraker, A.J., et al. "Modulation of histone acetylation by [4-(acetylamino)-N-(2-amino-phenyl) benzamide] in HCT-8 colon carcinoma." Mol. Cancer Ther. 2: 401-408 (2003).CI-994 in combination with traditional anti-cancer agents cytarabine (ara-C), daunorubicin and mitoxantrone resulted in a synergistic effect against acute myeloid leukemia (AML). Hubeek, I., et al. "CI-994 (N-acetyl-dinaline) in combination with conventional anti-cancer agents is effective against acute myeloid leukemia in vitro and in vivo." Oncol. Rep. 19: 1517-1523 (2008).CI-994 is a novel antitumor agent and had activity against 8 solid tumors tested including pancreatic ductal adenocarcinoma #02, pancreatic adenocarcinoma #03, colon adenocarcinoma #38, colon adenocarcinoma #51, mammary adenocarcinoma #25, mammary adenocarcinoma #17/ADR, Dunning osteogenic sarcoma and the human prostate carcinoma LNCaP. LoRusso, P.M., et al. "Preclinical antitumor activity of CI-994." Invest. New Drugs 14: 349-356 (1996).CI-994 inhibited the growth of two non-small cell lung cancer (NSCLC) cell lines, A-549 (adenocarcinoma) and LX-1 (squamous cell carcinoma), with an IC50 of 80 µM. It also showed synergism with standard anticancer agents such as gemcitabine and docetaxel. Loprevite, M., et al. "in vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell lines." Oncol. Res. 15: 39-48 (2005).